Tris Pharma, Inc.

Tris Pharma is considering all options when it comes to commercializing the novel drug cebranopadol for acute pain after a second Phase III trial read out positively. The company is on track to file c

Vertex Pharmaceuticals’ Journavx (suzetrigine) has gained US Food and Drug Administration approval for acute pain, but the question now is how well it might fare commercially, with analysts forecastin

Astellas Is Looking For Bolt-On Deals Astellas Pharma is looking to add new assets to its pipeline that could launch in the late 2020s or early in the next decade, chief strategy officer Adam Pearson

Tris Pharma is hoping to offer an alternative to opioid drugs for acute pain and has gotten a step closer to doing so with results from the Phase III ALLEVIATE-1 trial of cebranopadol in certain patie